Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(23/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(23/week)
News
United States
(594/week)
Manufacturing
(436/week)
Energy
(328/week)
Technology
(473/week)
Other Manufacturing
(362/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Fingolimod
Mar 10, 2020
2020 Disease Analysis: Multiple Sclerosis - Sanofi to Co-Develop Digital Therapeutic for MS Patients
Mar 10, 2020
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera
Dec 05, 2019
FDA approves first generics of Gilenya
Oct 31, 2019
Pharmascience Inc. launches pms-FINGOLIMOD for the treatment of relapsing-remitting multiple sclerosis (MS) in adults
Oct 31, 2019
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Aug 13, 2019
Novartis' Gilenya, Sanofi's Aubagio, Biogen's Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement
May 28, 2019
EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
Apr 10, 2019
Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
Feb 04, 2019
Global Multiple Sclerosis Dynamic Market 2018-2026: Gilenya Sales will be Affected by Erosion of Generics and Launch in the Market of the Second Generation of S1P Receptor Modulators
Dec 11, 2018
Spherix Global Insights' Quarterly Update on the Multiple Sclerosis Market Reveals a Unique Role for Genzyme's Aubagio As the Only Oral Standard-Efficacy Therapy for First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Dec 04, 2018
Multiple Sclerosis (MS) Market Analysis, Market size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
May 11, 2018
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
May 11, 2018
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
Mar 27, 2018
Uptake of Merck KGaA's Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals
Oct 28, 2017
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
Aug 11, 2017
Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Novartis' GILENYA®
Latest News
May 3, 2024
Industrias Unidas, S.A. de C.V. Consolidated Audited Results of Operations for Q4 2023
May 3, 2024
Cambridge-Lee Holdings Consolidated Results of Operations for FY 2023
May 3, 2024
Forum Energy Technologies Announces First Quarter 2024 Results, Benefits from Variperm Acquisition
May 3, 2024
Kolibri Global Energy Announces Annual 2023 Net Income of US$19.3 Million and Adjusted EBITDA of $39.1 Million
May 3, 2024
Magellan Aerospace Corporation Announces Financial Results
May 3, 2024
Bonnell Aluminum Commenting on Preliminary Dumping Determinations
May 3, 2024
Alliant Energy Announces First Quarter 2024 Results
May 3, 2024
Illinois American Water Proudly Recognizes American Water Charitable Foundation 2024 Water and Environment...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events